x

Ncardia and Nanion Technologies Sign Co-Marketing and Support Agreement to Enhance Options for Cardiac Researchers

19 September, 2018

Munich, Germany and Cologne, Germany, September 19, 2018 – Nanion Technologies GmbH (Nanion), a leading provider of instrumentation for ion channel drug discovery and screening, and the Ncardia Group (Ncardia), a leading developer, manufacturer, and service provider of human induced pluripotent stem cells (iPSCs) for safety and efficacy testing announced today that they have entered into a joint marketing and sales promotion agreement.

The partnership provides customers with high-performance instrument platforms from Nanion and Ncardia’s portfolio of hiPSC-derived cardiac cell types and assay services. Under the current one-year program, Nanion and Ncardia join forces to offer a menu of packages that address a spectrum of throughput requirements and budgets. The packages include state-of-the-art cell monitoring instrumentation: Nanion’s CardioExcyte 96 instrument with a SOL optical stimulation add-on option, and a supply of Ncardia's iPSC-derived cardiomyocytes – either frozen or delivered via the ‘ready-to-use’ CardioPlate™ range. Cor.4U® cardiomyocytes, validated in the CiPA consortium, are ideally suited for impedance applications, addressing structural as well as functional cardiotoxicity.

Additionally, users receive complementary initial training on site and comprehensive customer support from both Nanion (for CardioExcyte 96 and CardioExcyte 96 SOL optical stimulation add-on) and Ncardia (for cryopreserved cardiomyocytes or pre-plated iPSC-derived CardioPlate). Both Nanion and Ncardia are excited to co-develop and offer easier and more efficient scientific tools and support for customers under this program.

“The CardioExcyte 96 is a dual readout system, recording both contractility and electrophysiology of intact cardiomyocyte networks. The system is ideal for short and long-term cell monitoring and is therefore very well-matched not only for basic research but for safety and toxicity testing, as successfully shown in the phase II CiPA myocyte working group study, where Nanion took part” stated Niels Fertig, founder and CEO of Nanion Technologies GmbH. “In Ncardia, Nanion sees a strong business partner, but also a partner in development and science as demonstrated through our joint pioneering efforts in developing optogenetic stimulation solutions. This, and many other successful joint projects, brought us together in this program, as well.”

“Ncardia’s mission is to support and enable our clients to make better medicines faster. This partnership will provide scientists working in cardiovascular and neural safety and efficacy projects easier access to stem cell applications that accelerate drug discovery and development. Producing stem cell-derived models is only half the battle: the implementation of these cells in such informative, high-quality instrumentation that Nanion provides is really what drives the value of these technologies for R&D purposes” said Dr. Stefan Braam, CEO of Ncardia.

For more information please visit the Nanion and Ncardia websites.

Read more at BioInformant.

About Nanion:

Nanion is a leading provider of automated patch clamp (APC) electrophysiology systems with throughput capabilities ranging from a single cell up to fully automated high throughput screening (HTS) instruments recording from 768 cells simultaneously. Founded in 2002, Nanion has expanded its product range over the years to include in vitro systems for membrane pump and transporter recordings, bilayer recordings, and contractility measurements (impedance) from beating monolayers of cells, e.g. induced pluripotent stem cell-derived cardiac myocytes (iPSC-CMs), and confluency measurements of, e.g. hepatocytes for hepatotox screening using impedance. Nanion’s instruments combine high performance with user-friendly interfaces making them an ideal choice for academia, biotechnology, CROs and the Pharma industry. www.nanion.de

About Ncardia:

Ncardia (www.ncardia.com) is convinced that stem cell technology will help give patients faster access to better and safer medicines by improving the drug discovery and development process. The company develops and produces highly predictive human cellular assay systems for safety and efficacy testing of drug candidates. Ncardia provides applications and compound assay services such as of electrophysiology, biochemistry and contraction-based assays for predictive safety pharmacology and toxicology testing. Additionally, Ncardia offers cardiovascular services from disease modeling to high-throughput drug efficacy screening, as well as in-house assay development and support.

Ncardia is based in Belgium, the Netherlands, Germany and the USA. The company is privately held and established following the merger of Pluriomics and Axiogenesis.

www.ncardia.com

All product and company names herein may be trademarks of their registered owners.

Contact details
Dr Elena Dragicevic, Nanion Technologies GmbH
Phone: +49 89 219095 081
info@nanion.de

Dr Steven Dublin, Ncardia
Phone: +49 15 754743 427
info@ncardia.com

About CardioPlate

§